$0.55
-0.01 (-1.81%)
Open$0.55
Previous Close$0.56
Day High$0.57
Day Low$0.53
52W High$2.55
52W Low$0.53
Volume—
Avg Volume3.66M
Market Cap154.82M
P/E Ratio—
EPS$-0.49
SectorBiotechnology
Analyst Ratings
Strong Buy
11 analysts
Price Target
+2,681.4% upside
Current
$0.55
$0.55
Target
$15.22
$15.22
$10.64
$15.22 avg
$24.41
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 3.53M | 3.01M | 180.17M |
| Net Income | -70,662,397 | -54,179,721 | 5.71M |
| Profit Margin | -2,003.6% | -1,903.4% | 3.2% |
| EBITDA | -212,945,049 | -172,344,348 | 9.37M |
| Free Cash Flow | — | — | 5.00M |
| Rev Growth | +17.4% | +17.4% | +21.8% |
| Debt/Equity | 20.86 | 20.86 | 0.48 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $266.28 | +0.73% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $418.13 | +0.85% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $152.21 | +0.85% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $527.67 | +0.28% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | -4.54% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.36 | -0.23% | 41.4 | 33.44B |